Vaccination utilization among U.S. adults is low, and well below the Healthy People 2020 Targets, despite widespread availability of safe and effective vaccines and long-standing use recommendations by the Centers for Disease...more
The Department of Health and Human Services (HHS) has proposed a major, national payment model that would, if implemented, significantly impact how Medicare pays for drugs provided through the Part B program. Under the...more
Lessons From the Frontlines: Strategies for Supporting Informed Consumer Decision-Making in the Health Insurance Marketplace -
Editor's Note: As marketplaces prepare for the third open enrollment period, consumers are...more
7/23/2015
/ Admissions ,
Affordable Care Act ,
Anticompetitive Agreements ,
Attorney General ,
Biologics ,
Biosimilars ,
Caregivers ,
Centers for Medicare & Medicaid Services (CMS) ,
Decision-Making Process ,
Department of Justice (DOJ) ,
DSRIP ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Health Information Technologies ,
Health Insurance ,
Healthcare ,
Healthcare Reform ,
Healthcare.gov ,
Home Health Care ,
Home Healthcare Workers ,
Hospitals ,
Long-Term Care ,
Medicaid ,
Medical Malpractice ,
Medicare ,
Medicare Part B ,
Nurses ,
Patient Rights ,
Physicians ,
Prescription Drug Coverage ,
Prescription Drugs ,
Public Health Insurance Marketplace ,
Qualified Health Plans ,
Settlement ,
Sherman Act ,
State Health Insurance Exchanges
On April 15, 2015, CMS issued a preliminary recommendation for a HCPCS code for Zarxio, the first biosimilar product ever to be approved by the FDA. CMS’s recommendation provides the first indication of how the agency will...more